How aging "zombie" cells spark chronic inflammation — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers from Sanford Burnham Prebys, Mayo Clinic, and collaborating institutions published a study in Nature (2026; 656 (8129): 980) identifying how senescent "zombie" cells keep the immune system in a prolonged state of alert as the body ages.
- Two mitochondrial pathways converge to drive the senescence-associated secretory phenotype (SASP): elevated acetyl-CoA loosens DNA packaging to expose inflammatory genes, while damaged mitochondria leak DNA and RNA that trigger immune signals activating those same exposed genes.
- Senescent cells stop dividing but remain metabolically active, and their mitochondria produce excess acetyl-CoA that alters histones—the spool-like proteins DNA is wrapped around—making inflammatory genes more accessible without changing the genetic code itself.
- The drug CTPI-2, which blocks a transport protein needed to produce acetyl-CoA, reduced inflammation across multiple tissues and improved tissue function and healthspan in aging mice in experiments led by João Passos's lab at Mayo Clinic.
- Co-corresponding author Peter Adams, who directs the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys, said weakening the metabolic signal made SASP genes less accessible and produced functional benefits even though immune signaling from leaky mitochondria remained present.
- First author Hélène Martini, a postdoctoral researcher in the Passos lab, led the publication, with funding from the NIH, National Institute on Aging, Hevolution Foundation, Glenn Foundation for Medical Research, and Cancer Research UK.
Why it matters: The study reframes age-related inflammation as a two-part mitochondrial partnership rather than a single trigger, and shows that disabling only the metabolic half (via CTPI-2) still reduced inflammation and improved mouse healthspan. If the acetyl-CoA-blocking strategy translates to humans, it would offer a drug-based alternative to senolytic approaches that try to kill senescent cells outright.
Ask SkimNews
